LY-235959: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 24: | Line 24: | ||
{{stub}} | {{stub}} | ||
<gallery> | |||
File:LY-235959.svg|LY-235959 | |||
</gallery> | |||
Latest revision as of 00:23, 17 March 2025
LY-235959 is a compound used in scientific research, specifically in the field of neuropharmacology. It acts as a potent and selective antagonist for the NMDA receptor, and has been used in the study of various neurological and psychiatric disorders.
Pharmacology[edit]
LY-235959 is a non-competitive antagonist at the NMDA receptor, a type of ionotropic glutamate receptor. It binds to a site within the ion channel of the receptor, blocking the flow of ions and thereby inhibiting the receptor's function.
The NMDA receptor is involved in a wide range of physiological and pathological processes in the central nervous system. It plays a crucial role in synaptic plasticity, which is the ability of the connections between neurons to change in strength, and is thought to be a cellular mechanism underlying learning and memory.
Research Uses[edit]
Due to its selective action on the NMDA receptor, LY-235959 has been used in a variety of research contexts. It has been used to investigate the role of the NMDA receptor in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, as well as in psychiatric disorders such as schizophrenia and depression.
In addition, it has been used in studies of pain and analgesia, as the NMDA receptor is involved in the transmission and modulation of pain signals in the central nervous system.
